FDA has just approved a long-term injection to prevent HIV

The food of the United States and drug administration is only lenacapavir approved, an inexcable form of Hiv Prevention that is almost 100 percent effective and requires only two doses per year. Science The magazine described the medicine the most important scientific advance of the 2024.

In clinical processes, lenacapavir has tried 99.9 percent effective in prevention of hiv through sexual people in people who weigh more than 35 kilograms. The drug, an antitroviral, travel not stimulating a immune, but bygling the protein of the Virus’s protein viruses this happens as the body receives injections every six months.

Lenacaapavir has already been approved in some countries as a HIV Treatment in people with the forms of the virus that are resistant to other treatments. However, before this week, its USA practice has not been approved anywhere, that the decision to fD a significant development in Equidemics HIV / SEP

The drug is not the first medicine that can be taken preempted against a HIV infection: Prophet of the Prophet) Ebbi available in several countries, including the United States. But these should be taken every day, and assuring the continued access with these factories, and that people really remember not to remember them, is a known challenge. I am It is hoped the effective effects of lenacap it will make it easier for people to stay protected against the virus.

According to his Creator, Galad Science, Lenacopir will be Marketed Under Name TRADE NAME YUZTOO. The company engaged to manufacture 10 million doses from 2026.

“This is a historic day in the long-fighting deceptions against the HIV. YUGTGO is one of the most true science discoveries, the president and Galad’s CEO, has told the statement the Wednesday.

However, the price of Lenacapavir can be a barrier to access. Yeuttugo will have a $ 28.218 listing price per person in the United States. Winnie Byniaima, Executive Director of United Nations United Nations Director United on HIV / AIDS (ADS), also flag in the past May the drug is useless for many people in Africa, where medicine has the potential to have the greatest impact. About two thirds of the people who live with hi the world in the world in the world in the world in sub-saharan africa.

Galad said in a statement last year That has been “developing a strategy by activities to Sustainable Globaly” to Lenacapavir, She has the company has also provided detailed information about how it will do this. An option could be “voluntary license”, where other companies are granted to produce generic versions of an exclusively the countries. The researchers at Liverpool University in the UK they have calculated May the value of a year of LenacaPavir could be available for little $ 25.

This story has originally Wired in Spanish and has been translated by Spanish.